{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:03:50Z","timestamp":1703462630490},"reference-count":14,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Lab Physicians"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background\u2003Blood stream infections (BSIs) due to Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are associated with high mortality ranging from 10 to 60%. The current anti-MRSA agents have limitations with regards to safety and tolerability profile which limits their prolonged usage. Levonadifloxacin and its oral prodrug alalevonadifloxacin, a novel benzoquinolizine antibiotic, have recently been approved for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteremia in India.<\/jats:p><jats:p>Methods\u2003The present study assessed the potency of levonadifloxacin, a novel benzoquinolizine antibiotic, against Gram-positive blood stream clinical isolates (n = 31) collected from January to June 2019 at a tertiary care hospital in Mumbai, India. The susceptibility of isolates to antibacterial agents was defined following the Clinical and Laboratory Standard Institute interpretive criteria (M100 E29).<\/jats:p><jats:p>Results\u2003High prevalence of MRSA (62.5%), quinolone-resistant Staphylococcus aureus (QRSA) (87.5%), and methicillin-resistant coagulase-negative staphylococci (MR-CoNS) (82.35%) were observed among bacteremic isolates. Levonadifloxacin demonstrated potent activity against MRSA, QRSA, and MR-CoNS strains with significantly lower minimum inhibitory concentration MIC50\/90 values of 0.5\/1 mg\/L as compared with levofloxacin (8\/32 mg\/L) and moxifloxacin (2\/8 mg\/L).<\/jats:p><jats:p>Conclusion\u2003Potent bactericidal activity coupled with low MICs support usage of levonadifloxacin for the management of BSIs caused by multidrug resistant Gram-positive bacteria.<\/jats:p>","DOI":"10.1055\/s-0040-1720944","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T13:27:49Z","timestamp":1606224469000},"page":"230-232","source":"Crossref","is-referenced-by-count":1,"title":["In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital"],"prefix":"10.25259","volume":"12","author":[{"given":"Dhruv","family":"Mamtora","sequence":"additional","affiliation":[{"name":"Department of Microbiology, S.L. Raheja Hospital, Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjith","family":"Saseedharan","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, S.L. Raheja Hospital, Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritika","family":"Rampal","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Wockhardt Ltd., Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Joshi","sequence":"additional","affiliation":[{"name":"Drug Discovery Research, Wockhardt Research Center, Aurangabad, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallavi","family":"Bhalekar","sequence":"additional","affiliation":[{"name":"Department of Microbiology, S.L. Raheja Hospital, Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishid","family":"Ahdal","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Wockhardt Ltd., Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Wockhardt Ltd., Mumbai, Maharashtra, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/21505594.2015.1134072","article-title":"Bloodstream infections in the intensive care unit","volume":"7","author":"M Bassetti","year":"2016","journal-title":"Virulence"},{"issue":"02","key":"ref2","first-page":"363","article-title":"Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern","volume":"137","author":"Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group, India","year":"2013","journal-title":"Indian J Med Res"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/cc10114","article-title":"Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality","volume":"15","author":"J R Prowle","year":"2011","journal-title":"Crit Care"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1469-0691.2011.03679.x","article-title":"Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia","volume":"18","author":"M Bassetti","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3201\/eid1807.101371","article-title":"Predicting risk for death from MRSA bacteremia","volume":"18","author":"M Pastagia","year":"2012","journal-title":"Emerg Infect Dis"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jac\/dkp377","article-title":"Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?","volume":"65","author":"H M Nguyen","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1592\/phco.27.8.1189","article-title":"Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome","volume":"27","author":"M Narita","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dku513","article-title":"Comment on: efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials","volume":"70","author":"M H Potashman","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.50.3.1079-1082.2006","article-title":"Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus","volume":"50","author":"L Cui","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/AAC.00641-06","article-title":"The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase","volume":"50","author":"S S Bhagwat","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence","volume":"13","author":"S S Bhagwat","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"ref12","volume-title":"Clinical and Laboratory Standard Institute (CLSI)","year":"2018","edition":"11th ed"},{"key":"ref13","volume-title":"Clinical and Laboratory Standard Institute (CLSI)","year":"2019","edition":"29th ed"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkz493","article-title":"In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18","volume":"75","author":"B Appalaraju","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Laboratory Physicians"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1720944.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T08:16:53Z","timestamp":1703405813000},"score":1,"resource":{"primary":{"URL":"https:\/\/jlabphy.org\/in-vitro-activity-of-a-novel-benzoquinolizine-antibiotic-levonadifloxacin-wck-771-against-blood-stream-gram-positive-isolates-from-a-tertiary-care-hospital\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":14,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2020,11,23]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1720944","relation":{},"ISSN":["0974-2727","0974-7826"],"issn-type":[{"value":"0974-2727","type":"print"},{"value":"0974-7826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,23]]}}}